Rheumatoid arthritis does not follow a predictable pattern. Joints flare without warning, stiffness sets in overnight, and some mornings the simple act of making a cup of tea feels like a serious undertaking. For many people living with RA in the UK, standard treatments from NSAIDs and DMARDs to biologics, provide meaningful relief. For others, the symptoms remain difficult to manage despite years of trying.
Medical cannabis has been legally available on prescription in the UK since November 2018, and a growing body of evidence is examining its potential role in chronic inflammatory conditions, including rheumatoid arthritis.
Key Takeaways:
- Rheumatoid arthritis affects approximately 400,000 people in the UK and is two to four times more common in women than men.
- Medical cannabis has been legally available on prescription in the UK since November 2018, but has been prescribed fewer than five times via the NHS since legalisation. Most patients access it through specialist private clinics.
- The most studied potential benefits for RA include pain relief, reduced inflammation, improved sleep, and lower disease activity scores.
- Medical cannabis is not a first-line treatment. It is typically considered when other options have not provided sufficient relief.
- A specialist clinical assessment is required before any prescription is issued.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Medical cannabis treatment requires a consultation with a qualified specialist clinician. If you are currently taking prescribed medications for rheumatoid arthritis or any other condition, always inform your doctor or prescriber before starting any new treatment. Cannabis-based medicines can interact with certain drugs, including immunosuppressants and biologics. Whether medical cannabis is appropriate for you can only be determined by a GMC-registered specialist after a full clinical assessment. The information provided does not replace an individual clinical evaluation. To find out whether you may be eligible, visit LeafEase.
What Rheumatoid Arthritis Actually Does to the Body
Rheumatoid arthritis is an autoimmune condition in which the immune system mistakenly attacks the lining of the joints (synovium) triggering persistent inflammation, swelling, and pain. Unlike osteoarthritis, which results from wear and tear, RA is driven by an overactive immune response that can affect joints on both sides of the body simultaneously, as well as other organs including the heart and lungs.
Around 400,000 people in the UK are currently living with RA, and approximately 12,000 new cases are diagnosed each year. The condition is two to four times more common in women than men, with peak onset typically occurring in the 70s, though people of any age can be affected. [1]
What the Evidence Shows for RA
The evidence base for medical cannabis in rheumatoid arthritis is growing, though large-scale randomised controlled trials remain limited. The studies that exist suggest meaningful potential, particularly for pain, inflammation, and sleep.
The First Controlled Trial
The most directly relevant controlled trial was published in the journal Rheumatology in 2006 by Blake et al. at the Royal National Hospital for Rheumatic Diseases in Bath. In a double-blind, placebo-controlled study of 58 RA patients, a cannabis-based oromucosal spray containing THC and CBD was assessed over five weeks. Researchers measured pain on movement, pain at rest, morning stiffness, sleep quality, and disease activity. The cannabis-based medicine produced a statistically significant reduction in pain scores and meaningful suppression of disease activity compared to placebo. [2]
UK Real-World Evidence
More recent data comes from the UK Medical Cannabis Registry, which collects prospective patient-reported outcomes from people prescribed CBMPs at UK private clinics. A 2024 analysis published in the International Clinical Psychopharmacology journal, led by researchers at Imperial College London and involving clinicians from NHS trusts including St George’s Hospital and Southmead Hospital, assessed 82 patients with inflammatory arthritis. Initiation of CBMP treatment was associated with statistically significant improvements in pain severity, pain interference with daily life, overall health-related quality of life, anxiety scores, and sleep quality at one, three, six, and twelve months of follow-up. [3]
The Endocannabinoid System and Inflammation
The biological mechanism by which cannabinoids may affect RA is an active area of research. CB2 receptors are found in notably higher concentrations in the joint tissue of RA patients than in those with osteoarthritis, suggesting a direct biological role for the endocannabinoid system in inflammatory arthritis. THC and CBD interact with these pathways through different mechanisms, which is why many specialist prescribers consider combination formulations. [4]
When Standard Treatment Isn’t Enough
Consider a woman in her late fifties, diagnosed with seropositive rheumatoid arthritis seven years ago. She has been on two different DMARDs, one of which was discontinued due to gastrointestinal side effects. Her current regimen includes methotrexate and a short-acting NSAID taken as needed. Her rheumatologist considers her disease partially controlled, but she reports persistent pain most mornings, a fatigue that doesn’t lift until mid-morning, and disturbed sleep on most nights.
This is the profile that many UK specialist prescribers see. The question they are asked to answer is not whether RA is a serious condition but whether this patient’s current treatment has provided sufficient relief. When the answer is no, cannabis-based medicines enter the picture as a complementary option to be assessed individually, never as a replacement for her existing rheumatology care.
Which RA Symptoms May Respond to Medical Cannabis?
Based on available evidence and clinical experience from UK prescribers, the symptoms where cannabis-based medicines show most promise in RA include:
- Pain on movement and at rest. For patients whose pain is not well controlled despite existing medication, this is often the primary goal.
- Morning stiffness and overnight discomfort. Morning stiffness is among the most common outcomes that improved.
- Sleep disruption. Poor sleep both amplifies pain perception and impairs immune regulation. The UK Medical Cannabis Registry data showed improvements in sleep quality as one of the sustained outcomes across twelve months of follow-up.
- Anxiety and psychological burden. The Registry data also showed improvements in anxiety scores. Living with a chronic, unpredictable condition carries a psychological weight that standard rheumatology care does not always address directly.
One of the most common concerns raised by RA patients considering medical cannabis is whether treatment will leave them feeling groggy or mentally foggy the next morning, something that already disrupts the first hours of the day for many people with this condition. It is a legitimate concern, and the answer depends entirely on formulation.
CBD-dominant and lower-THC formulations are associated with significantly less next-day sedation than higher-THC options. At LeafEase, your prescribing clinician factors in your morning routine, whether you drive, your current medications, and your sensitivity profile before recommending a starting formulation. If the first approach does not feel right, the prescription is adjusted.
With LeafEase’s ongoing subscription model, the clinician who conducts your initial assessment remains your prescriber throughout. They know your history, your response to treatment, and your goals. Follow-up consultations are built into the LeafEase Advantage subscription alongside free home delivery, so you are not repeating your story from the start at every appointment. Consultations take place by video with GMC-registered specialist clinicians. Once a prescription is issued, medication is processed within 48 hours and delivered to your door in plain, discreet packaging with no indication of the contents on the outside.
If you are living with rheumatoid arthritis and your current treatment is not providing sufficient relief, check your eligibility in a few minutes to find out whether a consultation is the right next step.
Frequently Asked Questions
Can I access medical cannabis for rheumatoid arthritis on the NHS?
Medical cannabis has been prescribed fewer than five times via the NHS since its legalisation in 2018, and no cannabis-based medicine is specifically licensed for rheumatoid arthritis in the UK. For most patients, access means going through a specialist private clinic. A referral from your GP is not required, you can book an assessment directly with LeafEase.
Will medical cannabis interact with my RA medications?
This is an important clinical question. Cannabinoids can interact with certain drugs metabolised by the liver, including some immunosuppressants and biologics. Your prescribing clinician at LeafEase will review your full medication list as part of the assessment. Do not stop or adjust any existing RA medication without discussing it with your rheumatologist.
Is it a replacement for my current treatment?
No. Medical cannabis for RA is considered as a complement to existing care, not a replacement. The approach is to manage symptoms that are not sufficiently controlled by conventional treatment. Your rheumatology care continues alongside any cannabis-based prescription.
What does the assessment involve?
Your LeafEase consultation involves a video appointment with a GMC-registered specialist who will review your diagnosis, medical history, the treatments you have already tried, your current medications, and your goals. The assessment typically takes around 30 to 45 minutes. If cannabis-based medicine is appropriate, a prescription is issued following the appointment.
How quickly will I notice a difference?
Response times vary. Some patients report improvements in sleep quality within the first one to two weeks. Pain and stiffness outcomes tend to be assessed over a longer period, often one to three months. Your clinician will schedule follow-up appointments to review how the treatment is working and adjust where needed.
References
[1] NICE. (2018). Rheumatoid arthritis in adults: management (NG100). Available at: https://www.nice.org.uk/guidance/qs33/documents/briefing-paper [Accessed: 4 June 2026].
[2] Blake, D.R., Robson, P., Ho, M., Jubb, R.W. and McCabe, C.S. (2006). Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology, 45(1), pp.50–52. Available at: https://pubmed.ncbi.nlm.nih.gov/16282192/ [Accessed: 4 June 2026].
[3] Francis, A., Erridge, S., Holvey, C. et al. (2024). Assessment of clinical outcomes in patients with inflammatory arthritis: analysis from the UK Medical Cannabis Registry. International Clinical Psychopharmacology. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12122089/ [Accessed: 4 June 2026].
[4] Barrie, N. and Manolios, N. (2017). The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. European Journal of Rheumatology, 4(3), pp.210–218. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC5685274/ [Accessed: 4 June 2026].
